Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
147 hedge funds and large institutions have $654M invested in Orexigen Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 32 increasing their positions, 51 reducing their positions, and 18 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
52% more capital invested
Capital invested by funds: $431M → $654M (+$223M)
18% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $8.6M
15% more funds holding
Funds holding: 128 → 147 (+19)
37% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$17M |
| 2 |
LCP
Lamond Capital Partners
San Francisco,
California
|
+$9.5M |
| 3 |
FAM
Fred Alger Management
New York
|
+$6.54M |
| 4 |
Morgan Stanley
New York
|
+$5.29M |
| 5 |
Millennium Management
New York
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$9.9M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$9.5M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.33M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.43M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.75M |
OREX Hedge Fund Activity: Q4 2014 in Review
147 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q4 2014, worth a combined $654M — up 52% from $431M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new OREX positions and 18 closed out — a net gain of 21 holders — while 32 added to existing stakes and 51 trimmed.
The largest buyer was Samlyn Capital, adding an estimated $17M. The largest seller was Capital Research Global Investors, cutting an estimated $9.9M.
- 147 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q4 2014, up from 128 in Q3 2014.
- Funds reported $654M of Orexigen Therapeutics, Inc. stock for Q4 2014, up 52% quarter-over-quarter.
- 39 funds opened new Orexigen Therapeutics, Inc. positions in Q4 2014 and 18 closed out, a net change of +21 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q4 2014 was Samlyn Capital, an estimated $17M added.
- The largest Orexigen Therapeutics, Inc. seller in Q4 2014 was Capital Research Global Investors, an estimated $9.9M sold.
Based on aggregated 13F filings for Q4 2014.